Komori
Shimadzu (7701) · InitiativePrice revisions failed to offset higher costs

Improving Profitability Through Price Revisions

First written in FY2024-Q1. 2 of 4 entries say "Restated". Latest entry: FY2025.

4entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2024-Q1 – FY20252023: 220232024: 120242025: 12025
Same theme, other companies
Improving gross margin through appropriate pricing and restraint in price cutsA theme 52 companies write about · 5 as a headwind · 48 as a tailwind

The whole theme swung hardest in 2025: 5 of 36 companies on the "Worse" side.

1 other company's latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 52 companies compared. The sentences above are computed from all 52.
Full recordFilings, disclosures and news, newest first
  1. FY2025Price revisions failed to offset higher costsAnnual report

    「Although the company pursued price revisions, it was unable to offset the effects of higher material prices, increased growth investment in R&D and DX, and increased investment in personnel with the profit increase from higher sales. Operating profit was ¥71,720 million, down 1.4%.」

    Although the company pursued improved profitability through price revisions, operating profit declined because it was unable to absorb higher component prices and increased growth and personnel investments.
  2. FY2024-Q3RestatedAnnual report

    「The Company made growth investments, including investments in people, R&D and capital expenditures, while working to improve profitability by pursuing price revisions and other measures.」

    The company continues to pursue initiatives to improve profitability by advancing growth investments in human capital, research and development, and capital expenditures, alongside price revisions.
  3. FY2024-Q2RestatedAnnual report

    「Against this backdrop, sales increased in the healthcare and green sectors for key products, including liquid chromatographs, mass spectrometry systems and gas chromatographs. Production also recovered as shortages of parts and materials eased. Alongside growth investments in human resources, research and development, and capital expenditures, the Company also proceeded with price revisions to improve profitability.」

    The policy of pursuing price revisions in parallel with investment for growth and working to improve profitability has been reaffirmed.
  4. FY2024-Q1First statedAnnual report

    「Although operating profit was pressured by higher expenses from growth investments in people, R&D, and capital expenditure and by higher component and materials prices, it increased as higher sales of priority products and price revisions improved profitability.」

    Profitability improvement through price revisions was first identified independently, alongside higher sales of priority products, as a specific factor behind higher operating profit.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Shimadzu's next results are scheduled for 2026-11-06. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.